News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Bronchitol EU Marketing Authorisation Update
Pharmaxis today announced that the review of the European Marketing Application will not conclude as previously advised during Q4 2010.
At the Committee for Medicinal Products for Human Use (CHMP) meeting last week, it was agreed, that Bronchitol would be the subject of an oral explanation at the January meeting. Therefore, the review is now expected to conclude during Q1 2011.
Read full media release - pdfExtended Benefit with Bronchitol in Second Phase III Cystic Fibrosis Trial
Pharmaxis today announced positive first results for the open label component of its second international Phase III trial of Bronchitol in people with cystic fibrosis.
Read full media release - pdf
Pharmaxis Holds Pre-NDA Meeting with FDA for Bronchitol
Pharmaxis today announced that the Company held a pre-NDA meeting with the US Food and Drug Administration (FDA) on Friday 10 December 2010 .
Read full media release - pdf